Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC boosted its holdings in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 934.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 142,491 shares of the biotechnology company’s stock after purchasing an additional 128,715 shares during the period. International Assets Investment Management LLC owned approximately 0.13% of Coherus BioSciences worth $474,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Dorsey & Whitney Trust CO LLC acquired a new stake in shares of Coherus BioSciences during the third quarter valued at approximately $39,000. Princeton Global Asset Management LLC acquired a new stake in shares of Coherus BioSciences during the third quarter valued at approximately $39,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Coherus BioSciences by 430.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,880 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 10,454 shares during the period. ELCO Management Co. LLC acquired a new stake in shares of Coherus BioSciences during the third quarter valued at approximately $57,000. Finally, Sherbrooke Park Advisers LLC acquired a new stake in shares of Coherus BioSciences during the third quarter valued at approximately $66,000. Institutional investors and hedge funds own 72.82% of the company’s stock.

Coherus BioSciences Trading Down 4.5 %

NASDAQ:CHRS opened at $1.93 on Friday. Coherus BioSciences, Inc. has a 1 year low of $1.43 and a 1 year high of $8.22. The firm’s fifty day simple moving average is $2.36 and its 200 day simple moving average is $2.50. The firm has a market capitalization of $219.06 million, a PE ratio of -0.75 and a beta of 0.54.

Coherus BioSciences (NASDAQ:CHRS) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.39). The company had revenue of $91.52 million for the quarter, compared to analyst estimates of $105.30 million. As a group, analysts anticipate that Coherus BioSciences, Inc. will post -0.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird cut their price target on shares of Coherus BioSciences from $11.00 to $9.00 and set an “outperform” rating on the stock in a report on Tuesday, January 23rd. Truist Financial cut their price target on shares of Coherus BioSciences from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, January 23rd. Finally, HC Wainwright cut their price target on shares of Coherus BioSciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, March 20th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.29.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.